Moderna

MRNA-Q

NASDAQ:MRNA

161.91
8.90 (5.21%)
Moderna is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts. It focuses on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA. Moderna's technology platform inserts synthetic nucleoside-modified mRNA into human cells.
More at Wikipedia

Analysis and Opinions about MRNA-Q

Signal
Opinion
Expert
TOP PICK
TOP PICK
April 8, 2021
Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)
Show full opinionHide full opinion
Moderna (MRNA-Q)
April 8, 2021
Stockchase Research Editor: Michael O'Reilly MRNA is now a well known name in the production of COVID-19 vaccine and is only one of three that have received approval in the US. Purchase agreements amounted to $18 billion, allowing cash flow reserves of the company to balloon. The company is now working on a single-dose product that does not require extreme refrigeration. The pullback in the share price, and a forward PE of 9x earnings, offers a good entry level here. We would buy this with a stop loss at $90, looking to achieve $175 -- upside potential of 29%. Yield 0% (Analysts’ price target is $174.25)
Stockchase Research
Price
$133.290
Owned
_N/A
BUY
BUY
March 15, 2021
A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.
Show full opinionHide full opinion
Moderna (MRNA-Q)
March 15, 2021
A year ago, Moderna was a speculative, untested biotech stock. Now, they've had great success with their Covid vaccine. Their RN technology extends beyond this virus, so the stock has a runway with possible non-Covid blockbusters ahead.
Jim Cramer - Mad Money
Price
$143.650
Owned
Unknown
DON'T BUY
DON'T BUY
January 18, 2021
The stock is being priced and valued on emotion, it is hard to value. The average target is $148 a year out. However, there has been downgrades with price targets now lower than where it is at right now. This year, they will make a lot of money because of covid, but after, it is questionable. It will be volatile.
Show full opinionHide full opinion
Moderna (MRNA-Q)
January 18, 2021
The stock is being priced and valued on emotion, it is hard to value. The average target is $148 a year out. However, there has been downgrades with price targets now lower than where it is at right now. This year, they will make a lot of money because of covid, but after, it is questionable. It will be volatile.
COMMENT
COMMENT
December 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

Show full opinionHide full opinion
Moderna (MRNA-Q)
December 14, 2020

PFE-N vs. MRNA-Q. PFE-N is a much, much larger company. MRNA-Q is bringing their first product ever to market. PFE-N is well established and their vaccine is one of many products. They also have many drugs going off patent but their pipeline is looking better. PFE-N is not one of her core holdings but their earnings growth should improve over time.

Christine Poole
Price
$156.600
Owned
No
COMMENT
COMMENT
July 21, 2020

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

Show full opinionHide full opinion
Moderna (MRNA-Q)
July 21, 2020

They were one of the first to enter the COVID vaccine race. They stock has shot up from $16 to $90. They don't make any money, though. They're making progress with their vaccine, and are still testing it to ensure safe, mass use. He doesn't think they'll make much money if they produce the vaccine (JNJ said they wouldn't charge much for their vaccine). But Moderna would prove the quality of its technology if the produce an effetive vaccine. There's been heavy insider selling at oderna, but that's likely triggered by the huge stock run-up.

Paul Harris, CFA
Price
$81.685
Owned
Unknown
COMMENT
COMMENT
May 18, 2020

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.

Show full opinionHide full opinion
Moderna (MRNA-Q)
May 18, 2020

As mentioned in our May report to Stockchase subscribers, Moderna (with NIH) began Phase 1 testing for a vaccine back in March. If the drug pasts future tests, Moderna and Swiss drugmaker, Lonza, will produce the drug together. Monday’s news puts Moderna as the frontrunner in the vaccine race and lifted its stock 27% to 84% year-to-date.

Editor
Price
$68.140
Owned
Unknown
Showing 1 to 6 of 6 entries
  • «
  • 1
  • »

Moderna(MRNA-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 2

Stockchase rating for Moderna is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Moderna(MRNA-Q) Frequently Asked Questions

What is Moderna stock symbol?

Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q

Is Moderna a buy or a sell?

In the last year, 2 stock analysts published opinions about MRNA-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Moderna.

Is Moderna a good investment or a top pick?

Moderna was recommended as a Top Pick by Stockchase Research on 2021-04-08. Read the latest stock experts ratings for Moderna.

Why is Moderna stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Moderna worth watching?

2 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.

What is Moderna stock price?

On 2021-04-19, Moderna (MRNA-Q) stock closed at a price of $161.91.